Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%–40% of patients with locally advanced and borderline resectable PDAC. The effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Heiduk, Max, Plesca, Ioana, Glück, Jessica, Müller, Luise, Digomann, David, Reiche, Charlotte, von Renesse, Janusz, Decker, Rahel, Kahlert, Christoph, Sommer, Ulrich, Aust, Daniela E., Schmitz, Marc, Weitz, Jürgen, Seifert, Lena, Seifert, Adrian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746809/
https://www.ncbi.nlm.nih.gov/pubmed/36509285
http://dx.doi.org/10.1172/jci.insight.152761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746809/
https://www.ncbi.nlm.nih.gov/pubmed/36509285
http://dx.doi.org/10.1172/jci.insight.152761

Ejemplares similares